Pro-Dex Inc (PDEX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pro-Dex Inc stock (PDEX) is currently trading at $48.61. Pro-Dex Inc PE ratio is 14.06. Pro-Dex Inc PS ratio (Price-to-Sales) is 2.17. Analyst consensus price target for PDEX is $56.00. WallStSmart rates PDEX as Underperform.
- PDEX PE ratio analysis and historical PE chart
- PDEX PS ratio (Price-to-Sales) history and trend
- PDEX intrinsic value — DCF, Graham Number, EPV models
- PDEX stock price prediction 2025 2026 2027 2028 2029 2030
- PDEX fair value vs current price
- PDEX insider transactions and insider buying
- Is PDEX undervalued or overvalued?
- Pro-Dex Inc financial analysis — revenue, earnings, cash flow
- PDEX Piotroski F-Score and Altman Z-Score
- PDEX analyst price target and Smart Rating
Pro-Dex Inc
📊 No data available
Try selecting a different time range
PDEX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Pro-Dex Inc (PDEX)
PDEX trades at a significant discount to its Graham intrinsic value of $67.93, offering a 44% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Pro-Dex Inc (PDEX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, profit margin. Concerns around market cap. Fundamentals are solid but monitor weak areas for improvement.
Pro-Dex Inc (PDEX) Key Strengths (2)
Every $100 of shareholder equity generates $31 in profit
Strong profitability: $16 kept per $100 revenue
Supporting Valuation Data
Pro-Dex Inc (PDEX) Areas to Watch (7)
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.6x book value
Modest earnings growth at 8.20%
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 2.17x sales
Solid revenue growth at 11.10% per year
Moderate institutional interest at 32.12%
Pro-Dex Inc (PDEX) Detailed Analysis Report
Overall Assessment
This company scores 53/100 in our Smart Analysis, earning a C- grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 5.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Profit Margin. Profitability is solid with Return on Equity at 30.90%, Profit Margin at 15.70%.
The Bear Case
The primary concerns are Market Cap, Price/Book, EPS Growth. Some valuation metrics including Price/Sales (2.17), Price/Book (3.60) suggest expensive pricing. Growth concerns include Revenue Growth at 11.10%, EPS Growth at 8.20%, which may limit upside. Profitability pressure is visible in Operating Margin at 17.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 30.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 11.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Profit Margin) and negatives (Market Cap, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PDEX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PDEX's Price-to-Sales ratio of 2.17x trades 281% above its historical average of 0.57x (98th percentile), historically expensive. The current valuation is 2% below its historical high of 2.22x set in Mar 2026, and 4238% above its historical low of 0.05x in Feb 2009.
Compare PDEX with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Pro-Dex Inc (PDEX) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Pro-Dex Inc is a mature, profitable business with steady cash generation. Revenue reached 72M with 11% growth year-over-year. Profit margins of 15.7% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 30.9% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 4M in free cash flow and 4M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Pro-Dex Inc.
Bottom Line
Pro-Dex Inc is a well-established business delivering consistent profitability with 15.7% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(1 last 3 months)
| Insider | Type | Shares |
|---|---|---|
DOMINGO, ANGELITA REBAMONTAN Director | Buy | +18 |
Data sourced from SEC Form 4 filings
Last updated: 10:06:57 AM
About Pro-Dex Inc(PDEX)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.